Code of Massachusetts Regulations › 105 CMR - DEPARTMENT OF PUBLIC HEALTH › Title 105 CMR 720.000 - List Of Interchangeable Drug Products › Procedures for Amending List of Interchangeable Drug Products › Section 720.200 - Appendix A

Current through Register 1525, July 5, 2024
MASSACHUSETTS
LIST OF
INTERCHANGEABLE
				  DRUGS
Department of Public Health regulation
				  105 CMR
				  720.050 describes the
Massachusetts
				  List of Interchangeable Drugs
.
105 CMR
				  720.050(a)  calls for the
				  automatic adoption of all "A" rated drug products listed in the
				  "
Approved Drug Products with Therapeutic Equivalence
				  Evaluations
" and its supplements as published by the U.S. Food and
				  Drug Administration (FDA), Department of Health and Human Services. This
				  publication is commonly referred to as the "
Orange Book
". It
				  is reprinted by the U.S. Pharmacopeial Convention Inc. (USP) as
Volume
				  III
of the
USP DI
.
105 CMR
				  720.050(b)  allows for the
				  establishment of the
Massachusetts Additional List of Interchangeable
				  Drugs
(
Additional List
), and provides the criteria
				  upon which these drug products are approved.
All prescriptions written by generic name can be interchanged
				  if the drug is multi-source. To determine if a prescription written for a brand
				  name drug product is interchangeable in Massachusetts:
1. Look up the drug product by the brand name
				in the index or by generic name in the "
Approved Drug Products with
				Therapeutic Equivalence Evaluations
" ("
Orange Book
").
				The drug products are arranged alphabetically.
2. Compare the dosage form and strength of
				the drug product prescribed with the dosage form and strength of the same drug
				product in the "
Orange Book
".
3. If the same drug product, dosage form and
				strength has been assigned an "A" rating by FDA and is
not
listed on the
Exception List
contained within
				105 CMR
				720.050, the drug product is
				interchangeable.
4. If the drug
				product is not listed in the "
Orange Book
", refer to
				105 CMR
				720.050(b), the
Massachusetts Additional List of Interchangeable Drugs
(
Additional List
).
5. Look up the drug product by the generic
				name inthe
Additional List
. The drug products are arranged
				alphabetically.
6. Compare the
				dosage form and strength of the drug product prescribed with the dosage form
				and strength of the same drug product listed on the
Additional
				List
.
7. If the same drug
				product, dosage form and strength are listed, the drug product is
				interchangeable.
Copies of the "
Approved Drug Products with
				  Therapeutic Equivalence Evaluations
" and its supplements
				  ("
Orange Book
") are available from the:
U.S. Food and Drug Administration
Department of Health and Human Services
Government Printing Office
Washington, D.C. 20402-9371
OPC 6768
(202) 783-3238
and
www.fda.gov/cder/drug
Copies of the
USP DI
(third volume of
USP DI
is the "
Orange Book
") are available
				  from:
The United States Pharmacopeial Convention, Inc.,
12601 Twinbrook Parkway
Rockville, MD 20852
(301) 881-0666
Copies of the
Massachusetts Additional List of
				  Interchangeable Drug Products
(document number
				  105 CMR 720.000) are
				  available from:
The State House Bookstore Room 116
Boston, MA 02133
(617) 727-2834
and
www.magnet.state.ma.us/dph/dcp/Drug
Formulary/Drug Interchange
TABLE OF CONTENTS
Foreword
Introduction
Drug Product Problem Reporting Instructions
Exception List
Format of the
Additional List
NDA, ANDA, Applicant (name) Changes
Abbreviations
Massachusetts Additional List of Interchangeable Drugs
				  (Alphabetical list of Official (Generic) Drug Names)
Parti al Proprietary Brand Cross-reference
FOREWORD
The
Massachusetts List of Interchangeable
				  Drugs
, is prepared by the Drug Formulary Commission (DFC) and the
				  Department of Public Health. The DFC is comprised of nine men and women
				  appointed by the Governor for the express purpose of developing a list of those
				  drug products that are safely interchangeable -- that is, equivalent to each
				  other in all significant respects. The DFC was established by M.G.L. c. 17,
				  § 13. This law was enacted with the intent of saving money for consumers
				  ofprescription drugs, since drug products that are marketed under trademark or
				  proprietary names are often available in the generic forms from competing
				  manufacturers at substantially lower prices. M.G.L. c. 112, § 12D mandates
				  prescription forms that allow practitioners to prescribe interchangeable drug
				  products by simply signing the signature line. If a practitioner determines
				  that a brand name drug product should be dispensed, he/she must sign the
				  signature line and write the words "
no substitution
" in his/her
				  own handwriting in the space provided below the signature line.
The regulations call for the automatic adoptionof "A"rated
				  drugproducts listed in the "
Approved Drug Products with Therapeutic
				  Equivalence Evaluations
" and its supplements (commonly referred to as
				  the "
Orange Book
") as published by the U.S. Food and Drug
				  Administration, Department of Healthand Human Services, plus a list of
				  additional drug products, the
Massachusetts Additional List of
				  Interchangeable Drugs
("
Additional List
"),
				  individually reviewed and approved by the DFC and the Department. The
				  regulations provide the criteria upon which the drug products listed on the
Additional List
are approved for interchange. The regulations
				  also provide the DFC and the Department with the authority to review any "A"
				  rated drug product listed in the "
Orange Book
" or drug product
				  approved for interchange on the
Additional List
and delete it
				  from the list of interchangeable drug products if deemed appropriate. Drug
				  products assigned an "A" rating by FDA which are deleted from the Massachusetts
List
are placed on the
Exception List
. Drug
				  products listed on the
Additional List
which are subsequently
				  deleted are removed from the
Additional List
.
Of the many factors considered by the Commission in
				  determining which drugs to include on the
List
, equivalent
				  safety and effectiveness are paramount. The Commission reviews evidence on
				  bioequivalence and pharmaceutical equivalence and includes on the
List
only those drug products determined to be fully
				  interchangeable and whose manufacturers are approved by the U.S. Food and Drug
				  Administration. Practitioners may prescribe any drug that appears on the
List
with confidence that it is as safe and effective as its
				  brand name counterpart.
The efforts of the Commission in the assessment and
				  evaluation ofdata and the preparationofthe
List
are to be
				  commended. The Department presents the
Massachusetts List of
				  Interchangeable Drugs
with pride and with confidence that the
List
will greatly benefit consumers throughout the
				  Commonwealth.
INTRODUCTION
INTERCHANGEABLE (GENERIC) DRUG LAW
In 1976 the Massachusetts Legislature passed an Act Further
				  Regulating the Establishment of a Formulary of Interchangeable Drug Products
				  (St. 1976, c. 470, § 13), commonly known as the Generic Drug Law. This
				  law, enacted to promote and regulate the use of generic drugs, created the Drug
				  Formulary Commission to develop a list of interchangeable drug products and
				  also required the use of a standard prescription form to encourage
				  practitioners to prescribe generic drugs.
PRESCRIPTION FORM
M.G.L. c. 112, § 12D mandates prescription forms with
				  one signature line. Ifthe prescriber signs the prescription form and writes the
				  words "
no substitution
" in his/her own handwriting in the space
				  provided below the signature line, the pharmacist must fill the prescription
				  exactly as indicated, with no interchange permitted. However, if the prescriber
				  signs the prescription and does not write "
no substitution
" under
				  his/her signature, the pharmacist is legally required to dispense a less
				  expensive, equivalent interchangeable drug product listed in the
Massachusetts List of Interchangeable Drugs
if one is
				  reasonably available.
MASSACHUSETTS LIST OF INTERCHANGEABLE
				  DRUGS
The
Massachusetts List of Interchangeable
				  Drugs
(MLID) consists of the "A" rated drug products listed in the
				  "
Approved Drug Products with Therapeutic Equivalence
				  Evaluations
" and its supplements as published by the U.S. Food and
				  Drug Administration, Department of Health and Human Services ("
Orange
				  Book
") and the
Massachusetts Additional List of
				  Interchangeable Drugs
(
Additional List
). The
Additional List
is developed by the Drug Formulary Commission.
				  The Commission determines drug products to be interchangeable only when they
				  meet certain criteria:
(a) the drug
				product is available from more than one source, with the same active ingredient
				in the same dosage form and strength;
(b) its manufacturer is approved by the U.S.
				Food and Drug Administration (FDA); and
(c) when essential to therapeutic outcome,
				the manufacturer of the drug has documented clinical evidence of
				bioequivalence.
The Commission judges that all the drugs included on the MLID
				  meet these standards and are bioequivalent, if essential, based on assessment
				  and evaluation of the U.S. Pharmacopeia and its supplements, other state and
				  hospital formularies, listings of the U.S. Department of Health and Human
				  Services of the FDA, and on the expertise of its members.
The
List
does not include:
(a) drugs that are protected by patent rights
				or available from only one source;
(b) many controlled-release and enteric
				coated drug products since they may not consistently deliver the same
				quantities of their active ingredients;
(c) those drugs for which the Commission had
				any significant doubt about safe interchange between manufacturers;
				and
(d) any drug for which
				bioequivalence is considered essential but for which bioequivalence has not
				been demonstrated or an appropriate standard for bioequivalence has not been
				established.
Bioequivalence is determined to be necessary for a particular
				  drug when bioinequivalence might result in therapeutic failure or hazard to the
				  patient. Bioequivalent drug products do not show a significant difference in
				  the rate and extent of absorption when administered at the same dosage under
				  similar conditions. Drugs that are equivalent in the extent to which they are
				  absorbed into a patient's body that differ in the rate of absorption may be
				  therapeutically equivalent -- having the same medical effect -- either because
				  the rate of absorption is not essential to the attainment of effective body
				  concentrations of the drug, or because the difference in the rate is otherwise
				  considered medically insignificant. Bioequivalence is a primary consideration
				  for those drug products with a narrow therapeutic/toxic dosage range (when
				  variation in the rate orextent of absorption could have a critical effect)
				  where careful determination of the correct dosage and monitoring of the patient
				  is essential to safe and effective use. To determine for which drugs
				  bioequivalence is essential, the Commission relies on expert medical testimony,
				  studies done by the pharmaceutical industry, the knowledge and expertise of the
				  individual members of the Commission, and advice from the FDA.
All drug products manufactured by FDA approved firms are
				  considered safe and effective for their intended use, even if the product has
				  not been included in the MLID. A practitioner may begin a patient's therapy
				  with a drug product from any manufacturer who has been approved by the FDA,
				  even though interchange of the drug once the dosage has been calculated for the
				  individual is not advised.
Several generic drug products are manufactured under the same
				  new drug application (NDA) as the brand name drug products. According to
				  section 1.6 of the
Orange Book
, drug products with the same
				  NDA are therapeutically equivalent. Massachusetts regulations allow the
				  interchange of these products. Distributors or repackagers of drug products
				  manufactured under the same NDA as the brand name product are not identified in
				  the
Orange Book
. Pharmacists who may not be able to determine
				  if drug products are interchangeable should contact the manufacturers,
				  distributors or repackagers. In addition the Department maintains an unofficial
				  list of these products.
Information relative to the Interchangeable (Generic) Drug
				  Law may be obtained from the Department of Public Health, Division of Food and
				  Drugs, 305 South Street, Jamaica Plain, MA 02130, telephone number (617)
				  727-2670, and from the Boards of Registration in Medicine, Dentistry and
				  Pharmacy.
DRUG PRODUCT PROBLEM REPORTING
				  INSTRUCTIONS
Since 1971 the United States Pharmacopeia (USP), in
				  cooperation with various professional associations and the Food and Drug
				  Administration (FDA), has operated the
Drug Product Problem Reporting
				  Program
. This program can be utilized by pharmacists, physicians, or
				  consumers to report any product problems encountered when using drugs
				  interchanged under the Massachusetts generic drug law. The program is product
				  oriented, and patient identification not requested. Should you prefer to remain
				  anonymous, so indicate to the USP and your name will be withheld from the
				  manufacturer and the FDA. Your participation in reporting problems will help to
				  ensure that the drug products prescribed and dispensed in Massachusetts are of
				  continued high quality.
Reports should be sent to The United States Pharmacopeial
				  Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852, (301) 881-0666.
				  The USP is an impartial, non-governmental organization concerned with drug
				  standards and quality control. After USP receives a report, copies are
				  forwarded to the FDA and to the manufacturer of the product involved. Either
				  the FDA or the manufacturer may act to investigate or correct problems.
EXCEPTION LIST
Orange Book
"A" rated drug products not
				  approved for interchange.
There are currently no products designated to be listed on
				  the Exception List.
ADDITIONAL LIST
The
Massachusetts Additional List of Interchangeable
				  Drugs
(
Additional List
) has been printed in a format
				  designed to be concise and understandable. Interchangeable drugs are listed
				  alphabetically according to their official (chemical or generic) names, and
				  separate sections in each listing show dosage forms, strengths, FDA approved
				  manufacturers, and categories.
DRUG
Drugs are listed in alphabetical order by their generic names
				  and are printed in capital letters. Drug products containing more than one
				  active ingredient (for example, CODEINE PHOSPHATE, GUAIFENESIN) are listed in
				  the conventional order of ingredients.
Only drug products grouped under single headings are to
				  be interchanged
.
DOSAGE FORM
Under the generic names are listed the various multisource
				  dosage forms in which a drug product is available. Abbreviations used for
				  dosage forms and approved manufacturers are found in the front of the
Additional List
.
Only identical dosage forms and strengths of identical
				  drugs are to be interchanged
.
STRENGTH
The approved strengths of the drug products are listed under
				  the heading "Strength(s)." The "strengths" must be read along with the "dosage
				  forms" since any strength shown is available only for the dosage form directly
				  to its left. Dosage strength is in metric units that are sometimes rounded off
				  from apothecary measures, which may introduce slight variations in the strength
				  of certain products. Single ingredient drug product strengths are separated by
				  commas. Combination drug products have a slash separating the strengths of the
				  individual ingredients. If more than one strength of a single component of a
				  combination drug product is approved, they will be separated by commas. For
				  example, the strength of a tablet of aspirin with codeine phosphate is "325mg /
				  15mg, 30mg, 60mg" which means that the combination is available with 325
				  milligrams of aspirin and 15, 30, or 60 milligrams of codeine phosphate. Drug
				  products with three or more components have their active ingredients listed
				  individually in parentheses and have slashes separating the strengths of the
				  individual ingredients.
MANUFACTURERS
Next to the heading "Manufacturers" are all approved
				  manufacturers for the drug product in that group, listed by three letter
				  abbreviations in capital letters. (See list of manufacturer abbreviations in
				  front of the
Additional List
.) Listed manufacturers have met
				  all legal requirements, including compliance with the FDA Good Manufacturing
				  Practices for the production of the drug product indicated. Approved
				  manufacturers hold current new drug applications (NDAs) or abbreviated new drug
				  applications (ANDAs) when required by law.
NDA, ANDA APPLICANT (NAME) CHANGES
Because it is not practical to identify in the
Massachusetts Additional List of Interchangeable Drugs
(
Additional List
) each and every product involved when an
				  applicant transfers its entire line of approved drug products to another
				  applicant, or when an applicant changes its name, these transfers and name
				  changes are identified in this section. In addition, the new manufacturers are
				  listed in parenthesis beside the original manufacturer under the
Manufacturers' Abbreviations
section of the
Additional
				  List
. Where only partial approved product lines are transferred
				  between applicants, each approved product involved will appear with the
				  manufacturer name change in the
Additional List
amendment.
Previously listed name changes have been incorporated
				  into the revised Manufacturers' Abbreviations section.
ABBREVIATIONS
The following abbreviations are used in the
Massachusetts List of Interchangeable Drugs
.
DOSAGE FORMS
aero
aerosol
amp
ampule
cap
capsule
conc
concentrate
e.c.
enteric-coated
elix
elixir
g
gram
Hbr
hydrobromide
HCl
hydrochloride
HC
hydrocortisone
inhl
inhalation
inhl liquid
inhalation liquid
inhl sol
inhalation solution
inj
injection
irr sol
irrigating solution
I.U.
international units
liq
liquid
lot
lotion
mcg
microgram
mEq
milliequivalents
mg
milligram
ml
milliliter
oint
ointment
ophth
ophthalmic
oral gran
oral granules for
reconstitution
oral powder
oral powder for
reconstitution
oral sol
oral solution
pow
powder
sol
solution
SR
sustained release
subl tab
sublingual tablet
supp
suppository
susp
suspension
syr
syrup
tab
tablet
top aero
topical aerosol
top swab
topical swab
U
units
vag
vaginal
MANUFACTURERS' ABBREVIATIONS
3MP
3M Pharmaceutical
AAA
Alpha Therapeutic
ABB
Abbott
ABI
Abic
ABL
Able Laboratories
ACI
ACIC Limited
ACP
Advanced Care Prod.
ADV
Advanced Remedies
AGV
Agvar Chemicals
AKO
Akorn
AKZ
Akzona Inc.
ALC
Alcon Labs
ALL
Allergan Pharmaceuticals
ALI
Alliance Pharmaceutical
ALP
Alpharma
APP
Alphapharm Party
ALT
Altana
ALZ
Alza Corp.
ALR
Alra Laboratories
AMA
Amaric
AMB
Ambix Labs
ACC
American Cyanamid Co.
AHP
American Home Products
ARL
American Regent Labs.
AME
Amersham
AMG
Amgen
AMI
Amide Pharmaceuticals
AMT
American Therapeutics
ANA
Anabolic
ANB
Anbex
ANC
Angus Chemical
ANE
Anesta
ANG
Angelini
APO
Apothecon
APK
Apothekernes
APP
American Pharmaceutical Partners
Inc
ARC
Arcola Labs.
APC
Arcum Pharmaceuticlal Corp.
ARP
Armenpharm
ARM
Armour Pharmaceuticals
ASC
Ascot Hospital Products
ASA
Asta
ASP
Astra Pharmaceuticals LP
ATH
Athena Neurosciences
BAK
Baker Norton
BAN
Banner Pharmacaps
BAP
Barlan Pharmacal
B/I
Boehringer Ingelheim
B/M
Boehringer Mannheim. Ther. Div
BAR
Barr Labs
BAS
Basel Pharmaceuticals
BAT
Bartor
B&L
Bausch & Lomb
BAY
Bayer Corp
BEA
Beach Prod.
B-D
Becton,Dickinson & Co.
BED
Bedford Laboratories
BEL
Bell
BDP
Beta Derm Pharmaceuticals
BER
Berlex
BFA
B.F. Asher
BHC
B.H. Chemicals
BID
Biodevelopment
BIO
Bio Technology General
BIV
Biovail
BLA
Blairex Laboratories
BLO
Block Drug Co.
BLU
Bluline
BRL
Blue Ridge Laboratories
BOC
Bock Pharmacal
BOW
Bowman Pharm.
BMS
Bristol Myers Squibb
BRC
Bracco Diagnostics
BRD
Bradley Pharm.
BRA
Braintree Laboratories
BRI
Bristol-Myers Prod.
BTG
BTG Pharmaceuticals
BVL
Ben-Venue Labs
BYR
Byron Chemical
C&M
C & M Pharmacal
CAD
Cadema Medical Products
CAG
Calgon Corp.
CDC
Carderm Capital
C-P
Chesebrough - Ponds
C-W
Cook - Waite
C/C
Chase Chemical
CSL
Chase Laboratories
C/P
Corvit Pharmaceuticals
CAL
Carlisle
CAM
Camall
CAR
Carnick Labs
CTW
CarterWallace
CEN
Century Pharmaceuticals
CBV
Cetus Ben Venue Therapeutics
CHA
Chamberlin Parenteral Corp.
CHE
Chelsea Laboratories
CHM
Chemed Corp.
CVO
Ciba Vision Ophthalmics
CIR
Circa Pharmaceuticals
CJD
Copanos, J.D.
CLA
Clay - Park
CLO
Clonmel Healthcare
CMB
C.M. Bundy
CMC
Consolidated Midland Corp.
C/T
Controlled Therapeutics
CMP
Carolina Medical Products
CNC
H.R. Cenci
COL
Colgate Palmolive
COM
Combe
CON
Connaught Laboratories
COO
Cooper Labs
COP
Copley Pharmaceutical
CPG
Consolidated Pharmacy Group
CRE
Creighton Products
CUM
Cumberland Swan
CUR
Curatex Pharmaceuticals
CTL
Central Pharmacal
D&G
Davis & Geck
D/L
DPT Laboratories
D-R
Del-Ray Laboratories Inc.
DAN
Danbury Pharmacal
DAR
Darby Group Companies
DEL
Dell
DEP
Deproco
DER
Dermik Laboratories
DES
Deseret Medical
DEY
Deylabs
DHL
DHL Laboratories
DIA
Dial Corp.
DIS
Dista
DMD
Duramed
DMG
D M Graham Laboratories
DOW
Dow Pharmaceutical
DPT
Dupont Pharmaceuticals
DPM
Dupont Merck
DUR
Dura Pharmaceuticals
DUN
Dunhall
DYN
Dynapharm
E/K
Eastman Kodak
EAT
Eaton Medical Corp.
ECR
ECR Pharmaceuticals
ELA
Elan Pharmaceuticals
ELL
Ellis Pharmaceuticals
EMP
EM Pharma
END
Endo
EON
Eon Laboratories
ENQ
Enquay Pharm
ENZ
Enzon
ESR
Elkins-Sinn/AH Robins
ERS
Ersana
ESI
ESI Lederle Generics
ESP
ESI Pharmacal
ETH
Ethicon Inc.
ETX
Ethex
ETK
Ethitek Pharmaceuticals
EVY
Everylife
EZC
E Z EM Co.
FAU
Faulding Pharm. Co.
FER
Ferndale
FRT
Ferrante
FRR
Ferring Labs
FIS
Fisons
FLE
Fleming & Co.
FOR
Forest
FOU
Fougera
FOY
Foy
FRE
Fresenius
G&W
G & W
GAL
Galderma
GEI
Geigy
GEC
Gencon
GED
Genderm
GET
Genentech
GEP
Genpharm
GEV
Geneva
GES
Gensia Sicor Pharmaceuticals Inc
GEZ
Genzyme
GIL
Gilbert Laboratories
GLD
Glades
GLW
GlaxoWellcome
GLE
Glenwood
GLO
Global Pharm.
G/P
Golden Pharms.
GOL
Goldine
GRE
Greenstone
GRI
Griffen,KW
G/L
Gruppo Lepetit
GUA
Guardian
GYM
GYMA Laboratories
GYN
Gynopharm
H-R
Holland-Rantos
HAL
Halsey Labs
HAM
Hamilton Pharmaceuticals
HAN
Hnford GC
HEA
Heather
HEN
Heran Pharmaceutical
HEX
Hexcel Chemical Products
HER
Hermal Pharmaceutical
HIC
Hickam
H/D
Hill Dermaceuticals
HIR
Hirsch Industries
HIT
Hi Tech Pharma
HTP
High Technology Pharmacal
HLC
Halocarbon
HCC
Hoechst Celanese Corp.
HMR
Hoechst Marion Roussell
HOE
Hoechst-Rousel
HOR
Horus Therapeutics
HOY
Hoyt
HUD
Hudson Pharmaceuticals
HUN
Huntington
HYB
Hybritec Inc.
HYG
Hygenics
HYR
Hyrex
IMM
Immunex
IMP
IMP Inc.
ICN
ICN Pharmaceuticals
IMS
International Medication
INP
Interpharm
INV
Invamed, Inc.
INW
Inwood Labs
ICC
Interchem Corp.
ILC
International Latex Corp.
ING
Ingram Pharmaceutical
INH
Inhalon
IOL
Iolab
IOM
Iomed
IPR
IPR Pharm
IVA
IVAX
J&J
Johnson & Johnson
JAC
Jacobus
JAN
Janssen Pharmaceuticals
JER
Jerome Stevens Labs
JRW
Johnson RW
JON
Jones Pharma Inc
KAL
Kalapharm
KBP
Kabi Pharmacia
KEE
Keene
KED
Kendall
KEN
Kenwood
KIN
King Pharmaceuticals
KIR
Kirkman Sales
KNO
Knoll
KPI
Key Pharmaceuticals
KVP
KV Pharmaceutical Co.
L/F
Labs Fournier
L/A
Laboratories Atral
LAF
Lafayette Pharms
LAN
Lannett
LED
Lederle
LEI
Leiras
LEK
Lek Ljubliana
LEM
Lemmon
LEO
Leo Pharms
LIF
Life Labs
LIL
Lilly
LIP
Liposome
LIQ
Liquipharm
LNK
LNK International
LOC
Loch Pharmaceuticals
LOR
Lorex
LOT
Lotus Biochemical
LPI
LPI Holding
LUI
Luitpold
LUS
Lek USA Inc.
LYN
LYNE Laboratories
M/P
Mallinckrodt Pharmaceutical.
MAY
Mayrand
MAT
Matrix Labs
MCG
Mcgaw
MCN
McNeil Consumer Products
MDP
MD Pharmaceuticals
MEA
Mead Johnson
MJN
Mead Johnson Nutritionals
M/R
Medco Research
MVA
Medeva
MEP
Medics Pharmaceuticals
MPI
Medi Physics, Inc.
MAG
Mepha AG
MER
Mericon
MET
Metronic
MGI
MGI Pharma
MID
Midway Medical
MIK
Mikart Laboratories
MIS
Mission Pharmacol
MJP
MJ Pharmaceuticals
MKL
Moore Kirk Labs
MLI
Marchar Laboratories
MLP
Miller Pharmacal
MLX
Milex
MMD
Marion Merrell Dow
MOR
Morton Grove
MCK
Merck & Co.
MSM
Marsam
MSL
Marshall Pharmacal
MTC
Martec
MOV
Mova
MUR
Muro
MUT
Mutual Pharmaceuticals
MYL
Mylan Pharmaceuticals
NEP
Nephron Pharmaceuticals Inc
NEU
Neutrogena
NOR
Norbrook Laboratories
N/W
Norton Waterford
N/N
Novo Nordisk
NEW
Newtron Pharmaceuticals
NHN
Norton HN
NOV
Novocol
NVP
Novopharm Ltd.
NUM
Numark
NYC
Nycomed
NYL
Nylos Trading
ORI
Organon, Inc.
OCL
Oclassen
OHM
OHM Laboratories
OMD
Ohmeda Pharmaceutical
OSA
On Site Azla
ODC
Ormont Drug & Chemical
OPC
Ortho Pharmaceuticals
OPT
Optopic Laboratories Corp.
ORG
Organics
OAP
Otsuka America Pharmaceutical
PAK
Pal-Pak
PAL
Palisades
P/D
Parke Davis
P/I
Plantex/Ikpharm
P/K
Purepac-Kalipharma
P/P
Parmed Pharmaceuticals
PAC
Paco Research
PAD
Paddock Labs
PHD
Pharmaderm
PAN
Panray
PAR
Par
PNL
Parnell
PER
Perrigo
PCE
Pharmachemie
PHC
Pharmics
PHK
Pharmakinetics Labs
PHM
Pharmeral
PHO
Phoenix Labs
PHS
Pharma Serve
PHT
Pharmaton
PFF
Pfeiffer
PFI
Pfizer
P/U
Pharmacia & Upjohn
P/A
Pharmaceutical Association
PIO
Pioneer Pharmaceutical Inc.
PPI
Physicians Products Inc.
PSA
Pharmaceutical Specialist Assoc
POH
Pohl Boskamp
POL
Polymedia
PGP
Prographarm
PRD
Professional Disposables
PRO
Proter Laboratory
PRI
Private Formulations
P&G
Proctor & Gamble
PRV
Pharmavite
PTK
Pharma-Tek
PUF
Purdue Frederick
PUR
Purepac
QUA
Quantum Pharmics Ltd.
QLT
QLT PhototherapeuticsInc.
RAN
Ranbaxy Pharmaceuticals
R/C
Reckitt & Colman
R&C
Reed & Carnrick
R/I
Research Industries
RXP
Rexar Pharmacal
RAC
Rachelle Labs
REN
Ren-Pharm Internatl. Ltd.
RHP
Rhone - Poulenc
RPR
Rhone-Poulenc Rorer
RAH
Robins, A.H.
REX
Rexall/Sundown
RIC
Richlyn Labs
ROC
Roche Labs.
RPF
Roerig/Pfizer
ROA
Roaco
RBP
Roberts Pharmaceutical
ROR
Rorer
ROS
Ross Labs
ROX
Roxane Labs
ROY
Royce Laboratories
RPC
Rosemont Pharmaceutical Corp
RUG
Rugby Labs
S-M
Spencer-Mead
S/W
Sanofi Winthrop
S/L
Schmid Laboratories
SAK
Sankyo
SAV
Savage Labs/Altana
SAN
Sandoz
SCE
Scherer, R.P.
SPI
Schein Pharmaceutical, Inc.
SCH
Schering Corporation
S/P
Schering/Plough
SWZ
Schwarz Pharma
SZG
SchwarzGMBH
SCI
ScinoPharm International
SCS
SCS Pharmaceuticals
SEA
Searle
SER
Serono Laboratories
SEQ
Sequus Pharmaceuticals
SHM
Sherwood Medical
SHI
Shionogi USA
SID
Sidmak Laboratories
SIG
Sigma Tau
SIX
Silarx
SKB
Smith, Kline Beecham
SBH
Sola Barnes Hind
SOL
Solopak Laboratories
SLV
Solvay
SOM
Somerset
SBM
Sorin Biomedics
SDP
Sperti Drug Products
STI
Steifel
STL
Stanlabs Pharmaceutical Co.
STR
Star Pharmaceuticals
STS
Steris Laboratories
STZ
Storz Ophthalmics
SUP
Superpharm
SPP
Suppositoria
SUR
Survival Technology
SYN
Syntex
SYO
Syosset Labs
TAB
Tablicaps
TAG
Tag Pharmaceuticals
TAK
Takeda
TAP
Tap Holdings
TAR
Taro Pharmaceutical
TAY
Taylor Pharmaceuticals
TEC
Technilab
THE
Theratech
THK
Therakos
THA
Thames Phamacol Co. Inc.
TIC
Tican Pharmaceuticals
TOP
Topiderm
T/L
Torch Laboratories
TOR
Torigian Lab
UDL
UDL Laboratories
UMD
Unimed
UPJ
Upjohn
USL
Upsher-Smith Labs
VAL
Vale Chemical
VAN
Vangard
VES
Vestal
VIC
Vicks Pharmacy Products
VIN
Vintage
VIR
Viratek
VIS
Vistakon, Inc.
VIV
Vivan Pharmacal
W-A
Wyeth Ayerst
W-C
Warner-Chilcott
WAW
Warner Wellcome
WRR
Warrick Pharm
WEP
WE Pharmaceuticals
WEN
Wendt Laboratories
WPP
West Point Pharma
WES
Westwood Squibb Pharmaceuticals
W-W
West-Ward
W/L
Wharton Labs
WBY
Whitby
WWT
Whiteworth Towne
WAL
Wallace Labs
WAR
Warner-Lambert
WAT
Watson Laboratories
WOC
Wockhardt
XTT
Xttrium Laboratories
YAM
Yamanouchi
YOS
Yoshitomi Laboratories
ZCA
Zeneca
ZGP
Zenith Goldline Pharmaceuticals
MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE
				  DRUGS
Click here to view
				  image
Click here to view
				  image
Click here to view
				  image
Click here to view
				  image
Click here to view
				  image
Click here to view
				  image
Click here to view
				  image
Click here to view
				  image
Click here to view
				  image
PARTIAL PROPRIETARY BRAND CROSS-REFERENCE
Generically equivalent drug products in the same strength and
				  dosage form listed in the
Additional List
are interchangeable
				  if their respective manufacturers are listed for that product. This partial
				  crossreference section does not attempt to list all brand names which are
				  approvedforinterchange. Formost products only one, usually the innovator or
				  most commonly prescribed brand, is listed below for quick reference
				  purposes.
See page 4105 for precise instructions for determining the
				  interchangeability of drug products.
BRAND SEE
(ATROPINE SULFATE, HYOSCINE HBr, HYOSCYAMINE HBr,
				  PHENOBARBITAL)
(THEOPHYLLINE, POTASSIUM IODIDE, ALCOHOL)
ACTIFED
				  ............................................................TRIPROLIDINE HCl,
				  PSEUDOEPHEDRINE HCl
ANDROID..............................................................................METHYLTESTOSTERONE
ANTABUSE DISULFIRAM
AQUAMEPHYTON.............................................................................
				  PHYTONADIONE
AURALGAN.........................................................................
				  BENZOCAINE, ANTIPYRINE
AZO-GANTANOL....................................................
				  SULFAMETHOXAZOLE, PHENAZOPYRIDINE
AZO-GANTRISIN
				  .......................................................SULFISOXAZOLE
				  PHENAZOPYRIDINE HCl
AZULFADINE
				  .................................................................................
				  SULFASALAZINE
BENADRYL
				  ............................................................................DIPHENHYDRAMINE
				  HCl
CYANOCOBALAMIN
BICILLIN............................................................................
				  PENICILLIN G BENZATHINE
BRETHINE
				  .............................................................................
				  TERBUTALINE SULFATE
CHLOR-TRIMETON.............................................................
				  CHLORPHENIRAMINE MALEATE
COL-BENEMID
				  .................................................................... PROBENECID
				  W/ COLCHICINE
CYCLANDELATE
DECADRON
				  .................................................................................
				  DEXAMETHASONE
DESQUAM
				  .................................................................................BENZOYL
				  PEROXIDE
DIMETANE DX................................ BROMPHENIRAMINE,
				  DEXTROMETHORPHAN, PSEUDOEPHEDRINE
DIUPRESS......................................................................CHLOROTHIAZIDE
				  W/ RESERPINE
DONNATAL...................................................................
				  ATROPINE SULFATE COMPOUND
DRAMAMINE
				  ...............................................................................DIMENHYDRINATE
DRIXORAL..................................................................................
				  (product reformulated)
ECONOPRED
				  .........................................................................
				  PREDNISOLONE ACETATE
ELIXOPHYLLINE KI
				  ......................................................... THEOPHYLLINE,
				  POTASSIUM IODIDE
EMPIRIN W/ CODEINE
				  .........................................................ASPIRIN W/ CODEINE
				  PHOSPHATE
ESTINYL
				  ..................................................................................
				  ETHINYL ESTRADIOL
EXNA.
				  ........................................................................................
				  BENZTHIAZIDE
FEDAHIST.............................................
				  PSEUDOEPHEDRINE HCl, CHLORPHENIRAMINE MALEATE
GLAUCON
				  ....................................................................................EPINEPHRINE
				  HCl
GRANULEX
				  ............................................................... TRYPSIN, BALSAM
				  PERU, CASTOR OIL
HALOTESTIN
				  .............................................................................FLUOX\YMESTERONE
HYCOMINE..........................................HYDROCODONE BITARTRATE W/
				  PHENYLPROPANOLAMINE
HYDROPRES
				  ........................................................... HYDROCHLOROTHIAZIDE
				  W/ RESERPINE
ISOPTO CARPINE
				  .............................................................................
				  PILOCARPINE HCl
ISORDIL
				  TEMBID.......................................................................
				  ISOSORBIDE DINITRATE
ISUPREL
				  ..................................................................................
				  ISOPROTERENOL HCl
KAON.
				  ...............................................................................
				  POTASSIUM GLUCONATE
KENALOG
				  .......................................................................
				  TRIAMCINOLONE DIACETATE
LARODOPA
				  .........................................................................................LEVODOPA
LEVSIN
				  .............................................................................
				  L-HYOSCYAMINE SULFATE
LIBRAX...........................................................
				  CHLORDIAZEPOXIDE W/CLIDINIUM BROMIDE
MANDELAMINE
				  ..................................................................METHENAMINE
				  MANDELATE
MEBARAL
				  ...................................................................................
				  MEPHOBARBITAL
MENEST
				  ...............................................................................ESTROGENS,
				  ESTERIFIED
METALONE T.B.A
				  ...................................................................PREDNISOLONE
				  TEBUTATE
MICRONASE
				  .......................................................................................
				  GLYBURIDE
MAGNESIUM SALICYLATE
NEO-SYNEPHRINE
				  .........................................................................
				  PHENYLEPHRINE HCl
CHLORAL HYDRATE
PAMELOR
				  .................................................................................NORTRIPTYLINE
				  HCl
PHENERGAN PLAIN
				  .......................................................................
				  PROMETHAZINE HCl
PONTOCAINE
				  .................................................................................TETRACAINE
				  HCl
PROSED.................................METHENAMINE
				  COMBINATION (METHENAMINE, PHENYLSALICYLATE,
ATROPINE SULFATE, HYOSCYAMINE, BENZOIC ACID METHYLENE
				  BLUE)
PROSTIGMINE
				  .................................................................NEOSTIGMINE
				  METHYLSULFATE
PYRIDIUM
				  ..............................................................................PHENAZOPYRIDINE
				  HCl
QUINAMM
				  ..................................................................................QUININE
				  SULFATE
SALUTENSIN
				  ...............................................................
				  HYDROFLUMETHIAZIDE, RESERPINE
SANOREX..........................................................................................
				  MAZINDOL
SERAPES..............................................
				  HYDRALAZINE HCl, HYDROCHLOROTHIAZIDE, RESERPINE
SLO-PHYLLIN GG
				  ................................................................. THEOPHYLLINE,
				  GUAIFENESIN
SLO-PHYLLIN
				  ....................................................... THEOPHYLLINE
				  (NON-SUSTAINED RELEASE)
SSKI.
				  ......................................................................................
				  POTASSIUM IODIDE
SUDAFED
				  ...............................................................................PSEUDOEPHEDRINE
				  HCl
SYNTHROID
				  .........................................................................LEVOTHYROXINE
				  SODIUM
TENUATE................................................................................
				  DIETHYLPROPION HCl
TESTOSTERONE
TUINAL
				  ......................................................AMOBARBITAL SODIUM,
				  SECOBARBITAL SODIUM
VASODILAN
				  .....................................................................................
				  ISOXSUPRINE